325 related articles for article (PubMed ID: 17454265)
1. Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases.
Miyake S; Yamamura T
Int Rev Immunol; 2007; 26(1-2):73-94. PubMed ID: 17454265
[TBL] [Abstract][Full Text] [Related]
2. The in vivo response of invariant natural killer T cells to glycolipid antigens.
Parekh VV; Lalani S; Van Kaer L
Int Rev Immunol; 2007; 26(1-2):31-48. PubMed ID: 17454263
[TBL] [Abstract][Full Text] [Related]
3. CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences.
Florence WC; Bhat RK; Joyce S
Expert Rev Mol Med; 2008 Jul; 10():e20. PubMed ID: 18601810
[TBL] [Abstract][Full Text] [Related]
4. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
5. Natural killer T cells and haemopoiesis.
Karadimitris A; Patterson S; Spanoudakis E
Br J Haematol; 2006 Aug; 134(3):263-72. PubMed ID: 16848769
[TBL] [Abstract][Full Text] [Related]
6. The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy.
Yu KO; Porcelli SA
Immunol Lett; 2005 Aug; 100(1):42-55. PubMed ID: 16083968
[TBL] [Abstract][Full Text] [Related]
7. The immunoregulatory role of CD1d-restricted natural killer T cells in disease.
van der Vliet HJ; Molling JW; von Blomberg BM; Nishi N; Kölgen W; van den Eertwegh AJ; Pinedo HM; Giaccone G; Scheper RJ
Clin Immunol; 2004 Jul; 112(1):8-23. PubMed ID: 15207777
[TBL] [Abstract][Full Text] [Related]
8. Invariant natural killer T cells and immunotherapy of cancer.
Molling JW; Moreno M; van der Vliet HJ; van den Eertwegh AJ; Scheper RJ; von Blomberg BM; Bontkes HJ
Clin Immunol; 2008 Nov; 129(2):182-94. PubMed ID: 18783990
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic manipulation of iNKT cells in autoimmunity: modes of action and potential risks.
Mars LT; Novak J; Liblau RS; Lehuen A
Trends Immunol; 2004 Sep; 25(9):471-6. PubMed ID: 15324739
[TBL] [Abstract][Full Text] [Related]
10. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity.
Wilson SB; Delovitch TL
Nat Rev Immunol; 2003 Mar; 3(3):211-22. PubMed ID: 12658269
[TBL] [Abstract][Full Text] [Related]
11. Immunoregulation of autoimmunity by natural killer T cells.
Linsen L; Somers V; Stinissen P
Hum Immunol; 2005 Dec; 66(12):1193-202. PubMed ID: 16690406
[TBL] [Abstract][Full Text] [Related]
12. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells.
Miyamoto K; Miyake S; Yamamura T
Nature; 2001 Oct; 413(6855):531-4. PubMed ID: 11586362
[TBL] [Abstract][Full Text] [Related]
13. Aging is associated with a rapid decline in frequency, alterations in subset composition, and enhanced Th2 response in CD1d-restricted NKT cells from human peripheral blood.
Jing Y; Gravenstein S; Chaganty NR; Chen N; Lyerly KH; Joyce S; Deng Y
Exp Gerontol; 2007 Aug; 42(8):719-32. PubMed ID: 17368996
[TBL] [Abstract][Full Text] [Related]
14. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide.
Jahng A; Maricic I; Aguilera C; Cardell S; Halder RC; Kumar V
J Exp Med; 2004 Apr; 199(7):947-57. PubMed ID: 15051763
[TBL] [Abstract][Full Text] [Related]
15. Invariant natural killer T (iNKT) cells in asthma: a novel insight into the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseases.
Oki S; Miyake S
Allergol Int; 2007 Mar; 56(1):7-14. PubMed ID: 17259804
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling reveals distinct functional attributes of CD1d-restricted natural killer (NK) T cell subsets.
Rolf J; Berntman E; Stenström M; Smith EM; Månsson R; Stenstad H; Yamagata T; Agace W; Sigvardsson M; Cardell SL
Mol Immunol; 2008 May; 45(9):2607-20. PubMed ID: 18304639
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic potential for ceramide-based activators of iNKT cells.
Berkers CR; Ovaa H
Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372
[TBL] [Abstract][Full Text] [Related]
18. NKT cells: T lymphocytes with innate effector functions.
Van Kaer L
Curr Opin Immunol; 2007 Jun; 19(3):354-64. PubMed ID: 17428648
[TBL] [Abstract][Full Text] [Related]
19. Understanding the behavior of invariant NKT cells in autoimmune diseases.
Yamamura T; Sakuishi K; Illés Z; Miyake S
J Neuroimmunol; 2007 Nov; 191(1-2):8-15. PubMed ID: 17905445
[TBL] [Abstract][Full Text] [Related]
20. Co-inhibitory roles for glucocorticoid-induced TNF receptor in CD1d-dependent natural killer T cells.
Chen S; Ndhlovu LC; Takahashi T; Takeda K; Ikarashi Y; Kikuchi T; Murata K; Pandolfi PP; Riccardi C; Ono M; Sugamura K; Ishii N
Eur J Immunol; 2008 Aug; 38(8):2229-40. PubMed ID: 18624295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
